IPSEN (IPN.PA) Stock Fundamental Analysis

EPA:IPN • FR0010259150

153.9 EUR
-0.8 (-0.52%)
Last: Feb 16, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

6

Overall IPN gets a fundamental rating of 6 out of 10. We evaluated IPN against 52 industry peers in the Pharmaceuticals industry. IPN is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. IPN has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • IPN had positive earnings in the past year.
  • In the past year IPN had a positive cash flow from operations.
  • Each year in the past 5 years IPN has been profitable.
  • In the past 5 years IPN always reported a positive cash flow from operatings.
IPN.PA Yearly Net Income VS EBIT VS OCF VS FCFIPN.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M 1B

1.2 Ratios

  • The Return On Assets of IPN (11.21%) is better than 76.92% of its industry peers.
  • IPN has a Return On Equity (17.93%) which is comparable to the rest of the industry.
  • With an excellent Return On Invested Capital value of 21.54%, IPN belongs to the best of the industry, outperforming 88.46% of the companies in the same industry.
Industry RankSector Rank
ROA 11.21%
ROE 17.93%
ROIC 21.54%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IPN.PA Yearly ROA, ROE, ROICIPN.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15 20 25

1.3 Margins

  • With a Profit Margin value of 13.25%, IPN perfoms like the industry average, outperforming 53.85% of the companies in the same industry.
  • IPN's Profit Margin has declined in the last couple of years.
  • IPN has a Operating Margin (25.32%) which is comparable to the rest of the industry.
  • IPN's Operating Margin has been stable in the last couple of years.
  • With an excellent Gross Margin value of 81.66%, IPN belongs to the best of the industry, outperforming 86.54% of the companies in the same industry.
  • IPN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 25.32%
PM (TTM) 13.25%
GM 81.66%
OM growth 3Y-3.38%
OM growth 5Y-1.48%
PM growth 3Y-18.1%
PM growth 5Y-11.16%
GM growth 3Y-0.97%
GM growth 5Y-0.21%
IPN.PA Yearly Profit, Operating, Gross MarginsIPN.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), IPN is creating value.
  • IPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IPN.PA Yearly Shares OutstandingIPN.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IPN.PA Yearly Total Debt VS Total AssetsIPN.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • IPN has an Altman-Z score of 4.87. This indicates that IPN is financially healthy and has little risk of bankruptcy at the moment.
  • IPN has a Altman-Z score of 4.87. This is in the better half of the industry: IPN outperforms 71.15% of its industry peers.
  • IPN has a debt to FCF ratio of 1.18. This is a very positive value and a sign of high solvency as it would only need 1.18 years to pay back of all of its debts.
  • IPN has a Debt to FCF ratio of 1.18. This is amongst the best in the industry. IPN outperforms 90.38% of its industry peers.
  • IPN has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
  • With a decent Debt to Equity ratio value of 0.19, IPN is doing good in the industry, outperforming 73.08% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 1.18
Altman-Z 4.87
ROIC/WACC2.65
WACC8.13%
IPN.PA Yearly LT Debt VS Equity VS FCFIPN.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

2.3 Liquidity

  • IPN has a Current Ratio of 1.96. This is a normal value and indicates that IPN is financially healthy and should not expect problems in meeting its short term obligations.
  • IPN has a Current ratio of 1.96. This is in the better half of the industry: IPN outperforms 69.23% of its industry peers.
  • A Quick Ratio of 1.79 indicates that IPN should not have too much problems paying its short term obligations.
  • IPN has a Quick ratio of 1.79. This is amongst the best in the industry. IPN outperforms 80.77% of its industry peers.
Industry RankSector Rank
Current Ratio 1.96
Quick Ratio 1.79
IPN.PA Yearly Current Assets VS Current LiabilitesIPN.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • IPN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 125.29%, which is quite impressive.
  • The Earnings Per Share has been decreasing by -4.10% on average over the past years.
  • IPN shows a strong growth in Revenue. In the last year, the Revenue has grown by 64.12%.
  • The Revenue has been growing slightly by 7.90% on average over the past years.
EPS 1Y (TTM)125.29%
EPS 3Y-11.98%
EPS 5Y-4.1%
EPS Q2Q%289.23%
Revenue 1Y (TTM)64.12%
Revenue growth 3Y7.57%
Revenue growth 5Y7.9%
Sales Q2Q%115.57%

3.2 Future

  • The Earnings Per Share is expected to grow by 2.92% on average over the next years.
  • IPN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.69% yearly.
EPS Next Y0.62%
EPS Next 2Y2.1%
EPS Next 3Y4.86%
EPS Next 5Y2.92%
Revenue Next Year3.73%
Revenue Next 2Y4.64%
Revenue Next 3Y5.11%
Revenue Next 5Y2.69%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
IPN.PA Yearly Revenue VS EstimatesIPN.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B
IPN.PA Yearly EPS VS EstimatesIPN.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 16.51, IPN is valued correctly.
  • Based on the Price/Earnings ratio, IPN is valued a bit cheaper than the industry average as 69.23% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 27.19, IPN is valued a bit cheaper.
  • With a Price/Forward Earnings ratio of 13.49, IPN is valued correctly.
  • IPN's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. IPN is cheaper than 76.92% of the companies in the same industry.
  • IPN is valuated cheaply when we compare the Price/Forward Earnings ratio to 28.06, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 16.51
Fwd PE 13.49
IPN.PA Price Earnings VS Forward Price EarningsIPN.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, IPN is valued cheaper than 96.15% of the companies in the same industry.
  • IPN's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. IPN is cheaper than 75.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 15.58
EV/EBITDA 5.87
IPN.PA Per share dataIPN.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • IPN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)26.51
PEG (5Y)N/A
EPS Next 2Y2.1%
EPS Next 3Y4.86%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. Dividend

5.1 Amount

  • With a yearly dividend of 0.95%, IPN is not a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 1.89, IPN has a dividend in line with its industry peers.
  • With a Dividend Yield of 0.95, IPN pays less dividend than the S&P500 average, which is at 1.82.
Industry RankSector Rank
Dividend Yield 0.95%

5.2 History

  • The dividend of IPN has a limited annual growth rate of 3.72%.
Dividend Growth(5Y)3.72%
Div Incr Years1
Div Non Decr Years4
IPN.PA Yearly Dividends per shareIPN.PA Yearly Dividends per shareYearly Dividends per share 2018 2019 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8 1

5.3 Sustainability

  • IPN pays out 14.95% of its income as dividend. This is a sustainable payout ratio.
  • IPN's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP14.95%
EPS Next 2Y2.1%
EPS Next 3Y4.86%
IPN.PA Yearly Income VS Free CF VS DividendIPN.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M
IPN.PA Dividend Payout.IPN.PA Dividend Payout, showing the Payout Ratio.IPN.PA Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

IPSEN

EPA:IPN (2/16/2026, 7:00:00 PM)

153.9

-0.8 (-0.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-12
Earnings (Next)07-29
Inst Owners15.35%
Inst Owner ChangeN/A
Ins Owners0.27%
Ins Owner ChangeN/A
Market Cap12.90B
Revenue(TTM)5.87B
Net Income(TTM)777.50M
Analysts69.47
Price Target135.82 (-11.75%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.95%
Yearly Dividend1.2
Dividend Growth(5Y)3.72%
DP14.95%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.97%
PT rev (3m)3.1%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)2.8%
EPS NY rev (3m)3.07%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.25%
Valuation
Industry RankSector Rank
PE 16.51
Fwd PE 13.49
P/S 2.2
P/FCF 15.58
P/OCF 11.15
P/B 2.97
P/tB 9.12
EV/EBITDA 5.87
EPS(TTM)9.32
EY6.06%
EPS(NY)11.41
Fwd EY7.41%
FCF(TTM)9.88
FCFY6.42%
OCF(TTM)13.8
OCFY8.97%
SpS70
BVpS51.74
TBVpS16.87
PEG (NY)26.51
PEG (5Y)N/A
Graham Number104.16
Profitability
Industry RankSector Rank
ROA 11.21%
ROE 17.93%
ROCE 27.02%
ROIC 21.54%
ROICexc 29.88%
ROICexgc 113.42%
OM 25.32%
PM (TTM) 13.25%
GM 81.66%
FCFM 14.11%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-3.38%
OM growth 5Y-1.48%
PM growth 3Y-18.1%
PM growth 5Y-11.16%
GM growth 3Y-0.97%
GM growth 5Y-0.21%
F-Score7
Asset Turnover0.85
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 1.18
Debt/EBITDA 0.4
Cap/Depr 52.58%
Cap/Sales 5.6%
Interest Coverage 250
Cash Conversion 54.79%
Profit Quality 106.48%
Current Ratio 1.96
Quick Ratio 1.79
Altman-Z 4.87
F-Score7
WACC8.13%
ROIC/WACC2.65
Cap/Depr(3y)123.84%
Cap/Depr(5y)123.25%
Cap/Sales(3y)11.93%
Cap/Sales(5y)11.8%
Profit Quality(3y)111.08%
Profit Quality(5y)104.31%
High Growth Momentum
Growth
EPS 1Y (TTM)125.29%
EPS 3Y-11.98%
EPS 5Y-4.1%
EPS Q2Q%289.23%
EPS Next Y0.62%
EPS Next 2Y2.1%
EPS Next 3Y4.86%
EPS Next 5Y2.92%
Revenue 1Y (TTM)64.12%
Revenue growth 3Y7.57%
Revenue growth 5Y7.9%
Sales Q2Q%115.57%
Revenue Next Year3.73%
Revenue Next 2Y4.64%
Revenue Next 3Y5.11%
Revenue Next 5Y2.69%
EBIT growth 1Y87.65%
EBIT growth 3Y3.94%
EBIT growth 5Y6.31%
EBIT Next Year24.19%
EBIT Next 3Y10.15%
EBIT Next 5Y4.57%
FCF growth 1Y522.48%
FCF growth 3Y4.75%
FCF growth 5Y5.6%
OCF growth 1Y26.34%
OCF growth 3Y5.92%
OCF growth 5Y8.44%

IPSEN / IPN.PA FAQ

What is the fundamental rating for IPN stock?

ChartMill assigns a fundamental rating of 6 / 10 to IPN.PA.


What is the valuation status of IPSEN (IPN.PA) stock?

ChartMill assigns a valuation rating of 5 / 10 to IPSEN (IPN.PA). This can be considered as Fairly Valued.


Can you provide the profitability details for IPSEN?

IPSEN (IPN.PA) has a profitability rating of 6 / 10.


What is the financial health of IPSEN (IPN.PA) stock?

The financial health rating of IPSEN (IPN.PA) is 7 / 10.


How sustainable is the dividend of IPSEN (IPN.PA) stock?

The dividend rating of IPSEN (IPN.PA) is 3 / 10 and the dividend payout ratio is 14.95%.